Patents by Inventor Jack W. Singer

Jack W. Singer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7173041
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: February 6, 2007
    Assignee: Cell Therapeutics Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Patent number: 7153864
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: December 26, 2006
    Assignee: Cell Therapeutics Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Publication number: 20030216414
    Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).
    Type: Application
    Filed: May 9, 2003
    Publication date: November 20, 2003
    Applicant: Cell Therapeutics,Inc.
    Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
  • Publication number: 20030216289
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: April 7, 2003
    Publication date: November 20, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Publication number: 20030211973
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: April 7, 2003
    Publication date: November 13, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Patent number: 6638938
    Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: October 28, 2003
    Assignee: Cell Therapeutics, Inc.
    Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
  • Publication number: 20020183243
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: January 22, 2002
    Publication date: December 5, 2002
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Patent number: 6420374
    Abstract: A family of compounds effective in suppressing lymphocyte activation is comprised of 7-(oxoalkyl)1,3-dialkyl xanthines, other than denbufylline, of the formula in which R1 and R2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group.
    Type: Grant
    Filed: November 6, 1996
    Date of Patent: July 16, 2002
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: James A. Bianco, Jack W. Singer, William J. Novick, Jr.
  • Publication number: 20020077290
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: September 20, 2001
    Publication date: June 20, 2002
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Publication number: 20020016285
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: March 19, 2001
    Publication date: February 7, 2002
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Patent number: 6057328
    Abstract: Disclosed are methods for treating conditions resulting from hyperoxia or mechanical ventilation comprising the administration of a compound of the formula: ##STR1## wherein R.sub.1 is a substantially pure resolved R enantiomer .omega.-1, secondary alcohol-substituted (C.sub.5-8) alkyl; and R.sub.2 and R.sub.3 are independently hydrogen atom or a (C.sub.1-12) alkyl optionally containing one or two oxygen atoms in place of non-adjacent carbon atoms.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: May 2, 2000
    Assignee: Cell Therapeutics, Inc.
    Inventors: Jack W. Singer, Edward Abraham
  • Patent number: 5985926
    Abstract: There is disclosed a method of preventing or delaying the occurrence of acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans by administering an effective amount of a compound that inhibits cellular signaling through a specific phospholipid-based cellular signaling and signal amplification pathway. The invention further provides a method for preventing or delaying clinical symptoms of a group of viral diseases wherein the viral disease is mediated by host cell viral replication. The invention provides an advantage by attacking host cellular signaling mechanisms to prevent the development of drug resistance from rapidly mutating viruses.
    Type: Grant
    Filed: February 10, 1997
    Date of Patent: November 16, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: David W. Leung, Gail E. Underiner, Jack W. Singer
  • Patent number: 5929081
    Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease and
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 27, 1999
    Assignee: Cell Therapeutics Inc.
    Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
  • Patent number: 5859017
    Abstract: In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allergen presentation or mast cell/basophil activation.
    Type: Grant
    Filed: April 1, 1994
    Date of Patent: January 12, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: Elisa Eiseman, Emer Clarke, Jack W. Singer, Stuart L. Bursten
  • Patent number: 5859018
    Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease and
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 12, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
  • Patent number: 5856115
    Abstract: There is disclosed a method for screening for inhibitors of cellular second messenger signaling regulated by lysophosphatidic acid acyl transferase (LPAAT) and phosphatidic acid phosphohydrolase (PAPH), which method comprises contacting target cells or appropriate subcullular elements under appropriate conditions of stimulation with a candidate drug and assessing the levels of the relevant subsets of phosphatidic acid (PA) and diacylglycerol (DAG) in the presence and absence of the candidate drug.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: January 5, 1999
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: James A. Bianco, Stuart L. Bursten, Jack W. Singer
  • Patent number: 5856331
    Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: January 5, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
  • Patent number: 5795898
    Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease and
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 18, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
  • Patent number: 5670507
    Abstract: There is disclosed a method for reversing the multiple drug resistant (MDR) phenotype in tumors insensitive to hydrophobic chemotherapeutic drugs due to over expression of mdr-1, comprising administering an effective amount of a long chain amino alcohol compound. There is further disclosed a method for preventing the development of MDR during cancer chemotherapy treatments, comprising administering during cancer chemotherapy treatments an effective amount of a long chain amino alcohol compound.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: September 23, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: Glenn C. Rice, Jack W. Singer
  • Patent number: 5585380
    Abstract: The specification discloses methods for modulating cellular metabolism in a subject, modulating being desirable to mitigate a condition of the subject. Disclosed methods include processes for administering to said subject an effective amount of a compound of the formula ##STR1## wherein one and only one of R.sup.1 and R.sup.3 is a straight-chain or branched-chain .omega.-hydroxyalkyl (5-8C), or is a branched-chain (.omega.-1)-hydroxyalkyl (5-8C), or is an (.omega.-1)-oxoalkyl (5-8C), or is an (.omega., .omega.-1) or (.omega.-1, .omega.-2)-dihydroxyalkyl (5-8C), or is an alkenyl substituent (5-8C), and the other is alkyl (1-12C) optionally containing one or two non-adjacent oxygen atoms in place of C.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: December 17, 1996
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: James A. Bianco, Stuart L. Bursten, Jack W. Singer